Issue link: http://www.e-digitaleditions.com/i/552614
Inhalation AUGUST 2015 21 Comprehensive particle characterization services Gateway Analytical provides comprehensive particle characterization services to identify the physical and chemical properties of the active ingredient and excipient components within a final formulation. Gateway's methods provide chemically-specific data on each particle, which allows them to easily identify and separate active ingredient from the excipients, and identify multiple active ingredients in more complex formulations. In addition, Gateway Analytical supports quality testing by providing an array of services for foreign particulate identification and contaminant source determination. Gateway Analytical US: +1 724 443-1900 www.gatewayanalytical.com Particle characterization ISSUE FOCUS New products for particle size measurement A new brochure from Copley Scientific, "Quality Solutions for Inhaler Test- ing, 2015 Edition," offers authoritative guidance on all aspects of aerody- namic particle size distribution measurement for both innovator and generic inhaled products. Recent additions to the company's extensive range for cas- cade impactor testing include accessories specifically for testing popular generics such as Fluticasone Propionate (FP) and Salmeterol, and the Breath Actuation Controller (BAC). The BAC 2000 is an ancillary for the measure- ment of more clinically relevant particle size data for metered dose inhalers with add-on devices, in accordance with the recently released draft US Phar- macopoeia (USP) chapter. Copley Scientific UK: +44 1159 616229 www.copleyscientific.com This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No product endorsement or preference is intended. Next Generation Impactor (NGI) MSP Corporation introduced the Model 170 Next Generation Impactor (NGI) in 2001 to improve the accuracy and convenience of particle size dis- tribution testing of inhalable drug products. Over a decade later, with more than 1,000 units in use worldwide, the NGI is now the industry global stan- dard. With a factory in-use-margin of no less than 50% on all of its all-316 stainless steel nozzle pieces, complete flow resistance characterization, con- trolled cup surface roughness and o-ring-free connections, there is only one NGI. MSP remains committed to manufacturing the NGI with utmost fidelity to its original design and solely to the highest standards of quality, including ISO 9001:2008. MSP Corporation US: +1 651 287-8100 www.mspcorp.com